Features of calcium-phosphorus metabolism and vitamin D metabolism in patients with chronic kidney disease at predialysis stages during bolus cholecalciferol therapy
Authors:
- A. S. BondarenkoABA. S. Bondarenko
- L. Ya. RozhinskayaLRL. Ya. Rozhinskaya
- A. Yu. ZhukovAZA. Yu. Zhukov
- V. A. IoutsiVIV. A. Ioutsi
- M. V. OvcharovMOM. V. Ovcharov
- G. S. KolesnikovaGKG. S. Kolesnikova
- A. I. SleptsovaASA. I. Sleptsova
- N. P. TrubitsynaNTN. P. Trubitsyna
- V. E. VinogradovVVV. E. Vinogradov
- O. N. KotenkoOKO. N. Kotenko
- E. A. PigarovaEPE. A. Pigarova
- Zh. E. BelayaZBZh. E. Belaya
- 1 April 2026
- journal article
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (1)
Abstract
Background . Chronic kidney disease (CKD) is associated with disturbances in calcium-phosphate homeostasis and vitamin D metabolism, leading in mineral and bone disorders (CKD-MBD). However, the pathogenetic features of these alterations at predialysis CKD stages and the effects of high-dose cholecalciferol therapy remain insufficiently characterized. Objective . To compare vitamin D metabolites and calcium-phosphate metabolism parameters in patients with predialysis CKD and individuals without impaired kidney function, and to assess their dynamics after a single bolus dose of 150,000 IU of cholecalciferol. Materials and Methods . The study included 58 participants: 23 patients with CKD stage C3, 14 with CKD stages C4-5, and 21 controls. Parameters of calcium-phosphate metabolism and vitamin D metabolites were assessed at baseline and 7 days after a single oral dose of aqueous cholecalciferol (150,000 IU). Vitamin D metabolites were measured using LC–MS/MS. Results . Data are presented as follows: control group, CKD C3, CKD C4-5. At baseline, CKD patients had higher parathyroid hormone (PTH) levels (51.3 [40.6; 62.7] vs 70.9 [49.0; 105.9] vs 101.0 [91.7; 120.1] pg/mL), lower calcitriol concentrations (40.9 [34.3; 59.4] vs 25.0 [19.8; 29.1] vs 26.4 [13.8; 30.6] pg/mL), a trend toward higher fibroblast growth factor 23 (FGF-23) levels (0.73 [0.43; 1.07] vs 1.08 [0.61; 2.52] vs 3.22 [1.78; 4.51] pmol/L), and a reduced 24,25 (OH) 2 D 3 /25(OH)D 3 ratio (0.06 [0.04; 0.08] vs 0.03 [0.01; 0.04] vs 0.03 [0.02; 0.04]), indicating impaired 24-hydroxylase activity. Total and free 25(OH)D levels and vitamin D-binding protein (VDBP) were comparable between groups. Seven days after cholecalciferol administration, a similar increase in total 25(OH)D 3 , 3-epi-25(OH)D 3 , and 24,25(OH) 2 D 3 was observed in all groups. However, the increase in free 25(OH)D was significantly smaller in CKD C3 and C4-5 compared with controls ( p =0.036 and p =0.028). PTH decreased in CKD C3 ( p =0.039), whereas FGF-23 increased in CKD C4-5 ( p =0.042). Serum calcium, phosphorus, calcitriol, and VDBP remained unchanged. Conclusion . Alterations in calcium-phosphate and vitamin D metabolism at predialysis CKD stages show a sequential pattern. Reduced vitamin D activation and inactivation, increased FGF-23 levels, and a blunted free 25(OH)D response to bolus cholecalciferol indicate specific regulatory features and limit the applicability of standard vitamin D correction regimens in this population.Keywords
This publication has 38 references indexed in Scilit:
- Bone Health ECHO Case Report: High Bone Mass in a Patient with Chronic Kidney DiseaseJournal of Clinical Densitometry, 2024
- Bone Health ECHO Case Report: Rare Cases of Hypophosphatemia and Low-Traumatic Fractures in Patients with Type 1 Diabetes MellitusJournal of Clinical Densitometry, 2024
- Baseline Characteristics of the DISCOVER CKD Prospective CohortAdvances in Therapy, 2024
- The effect of vitamin D supplementation on fibroblast growth factor‐23 in patients with chronic kidney disease: A systematic review and meta‐analysisPhytotherapy Research, 2021
- Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of GuidelinesCalcified Tissue International, 2021
- Chronic Kidney Disease—Mineral and Bone Disorders: Pathogenesis and ManagementCalcified Tissue International, 2020
- The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol StatusJBMR Plus, 2020
- Free vitamin D levels in steroid-sensitive nephrotic syndrome and healthy controlsPediatric Nephrology, 2019
- Reference intervals for serum 24,25-dihydroxyvitamin D and the ratio with 25-hydroxyvitamin D established using a newly developed LC–MS/MS methodThe Journal of Nutritional Biochemistry, 2017
- Vitamin D in chronic kidney diseaseBest Practice & Research Clinical Endocrinology & Metabolism, 2011